Biotherapy

, Volume 7, Issue 1, pp 27–37

Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon

  • J. A. Cabrera Gómez
  • J. R. Cordero Gutierrez
  • O. Fernández López
  • B. Reyes Gutiérrez
  • K. Romero Garcia
  • J. Simón Consuegra
  • R. Feas Cruz
  • A. González Quevedo
  • I. Alfaro Capdegille
  • M. Del Pino Falcón
  • S. Williams Serrano
  • M. Vega Galindo
  • P. López Saura
  • Y. Bello Rivero
Article

DOI: 10.1007/BF01878151

Cite this article as:
Gómez, J.A.C., Gutierrez, J.R.C., López, O.F. et al. Biotherapy (1993) 7: 27. doi:10.1007/BF01878151

Abstract

Twenty patients meeting DSM-III criteria for Schizophrenic Disorder, Paranoid Type were studied. After a 30 day drug-free period the patients were randomized in two groups. During a year, patients in Group 1 received intramuscular injections of a placebo while Group 2 received recombinant IFN alpha-2b. Both groups took anti-psychotic medication (APM) as needed on an individual basis, depending on their psychiatric symptomatology. Double blind evaluations, were performed at the beginning and at the end of the trial, using the Brief Psychiatric Rating Scale (BPRS) and the Reyes Scale for Social Evolution (RSSE). Information about relapses was gathered such as months without relapse, number and duration of the relapses and maximum dosages of APM given for relapse control. The statistical analysis of the results was performed with a matched pairs sign or Student's t tests for comparisons of each group before and after treatment. Groups were compared between them using the Fisher's exact test for frequencies and Student's t test for continuous variables. In Group 1: only one patient improved on the BPRS score; two had improved ratings on the RSSE; 2 patients got worse; and there were no changes in the rest of the group; three patients had no relapses and one increased in relapse frequency. These changes were not significant. The rate of relapses per year and their duration were not significantly modified in Group 1. The maximum dose of APM required for their relapse control was larger than before treatment although not significantly. All these patients required continuous APM. In Group 2 (IFN treated): 6 patients had improved BPRS scores (N=6, K=6, p<0.01) and 5 improved their RSSE scores (n=5, K=5, p<0.05). In 5 patients there were no relapses on their frequency decreased. There was significant reduction in the duration of the relapses (37.8±14.6 to 20.7±12.5 days; t=4.83; d.f.=9; p=0.0009) after treatment. Only 3 patients in Group 2 needed continuous APM after a relapse and the maximum dose required for control was significantly less (1281±527 to 687±552 chlorpromazine-equivalent mg. per day; t=5.56, p < 0.001). Comparisons between groups showed advantage for the IFN treated group in the BPRS change, proportion of patients needing continuous APM and integral evaluation. These results indicate that alpha IFN may be useful in the treatment of Schizophrenic Disorder, Paranoid Type.

Key words

Interferon alphaSchizophreniaintramuscular

Abbreviations

IFN

Interferon

CSF

cerebrospinal fluid

RSSE

Reyes Scale for Social Evolution

APM

antipsychotic medication

BBB

blood-brain barrier

mRNA

ribonucleic acid messenger

DSM-III

Diagnostic and Statistical Manual of Mental Disorders

JCG

Juan Cordero Gutierrez

OFL

Odalys Fernandez Lopez

BPRS

Brief Psychiatric Rating Scale

ECT

Electroconvulsive treatment

IgG

immunoglobulin G

EEG

Electroencephalogram

SD

standard deviation

CNS

Central Nervous System

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • J. A. Cabrera Gómez
    • 4
  • J. R. Cordero Gutierrez
    • 4
  • O. Fernández López
    • 4
  • B. Reyes Gutiérrez
    • 4
  • K. Romero Garcia
    • 4
  • J. Simón Consuegra
    • 4
  • R. Feas Cruz
    • 4
  • A. González Quevedo
    • 1
    • 4
  • I. Alfaro Capdegille
    • 1
    • 4
  • M. Del Pino Falcón
    • 1
    • 4
  • S. Williams Serrano
    • 2
    • 4
  • M. Vega Galindo
    • 2
    • 4
  • P. López Saura
    • 3
    • 4
  • Y. Bello Rivero
    • 3
    • 4
  1. 1.Instituto de Neurología y NeurocirugíaLa HabanaCuba
  2. 2.Facultad de Ciencias Médicas de CienfuegosCuba
  3. 3.Centro de Investigaciónes BiológicasLa HabanaCuba
  4. 4.Hosp. Provincial “Dr. Gustavo Aldereguía”CienfuegosCuba